tiprankstipranks
Repligen Corp (RGEN)
NASDAQ:RGEN
US Market
RGEN
Repligen
RESEARCH TOOLSreports

Repligen (RGEN) Stock Forecast & Price Target

978 Followers
See the Price Targets and Ratings of:

RGEN Analyst Ratings

Strong Buy
13Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Repligen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RGEN Stock 12 Month Forecast

Average Price Target

$190.00
▲(61.32% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $190.00 with a high forecast of $220.00 and a low forecast of $165.00. The average price target represents a 61.32% change from the last price of $117.78.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","143":"$143","169":"$169","195":"$195","221":"$221"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$220.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$190.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$165.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,143,169,195,221],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.32,126.14153846153846,133.96307692307693,141.7846153846154,149.60615384615383,157.4276923076923,165.24923076923076,173.07076923076923,180.8923076923077,188.71384615384613,196.5353846153846,204.35692307692307,212.17846153846153,{"y":220,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.32,123.83384615384615,129.3476923076923,134.86153846153846,140.3753846153846,145.88923076923078,151.40307692307692,156.91692307692307,162.43076923076922,167.9446153846154,173.45846153846153,178.9723076923077,184.48615384615385,{"y":190,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.32,121.91076923076922,125.50153846153846,129.09230769230768,132.68307692307692,136.27384615384614,139.86461538461538,143.45538461538462,147.04615384615386,150.63692307692307,154.2276923076923,157.81846153846152,161.40923076923076,{"y":165,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":128.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.12,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$220.00Average Price Target$190.00Lowest Price Target$165.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum Analyst forecast on RGEN
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
03/24/26
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Amylyx Pharmaceuticals Inc (AMLX)
H.C. Wainwright Analyst forecast on RGEN
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$208
Buy
76.60%
Upside
Reiterated
03/23/26
Repligen: Strong Execution, Innovation, and Cross‑Selling Momentum Support Sustained Growth and Reaffirmed Buy Rating
Wells Fargo Analyst forecast on RGEN
Brandon Couillard
Wells Fargo
Wells Fargo
$190→$180
Buy
52.83%
Upside
Reiterated
02/25/26
Repligen price target lowered to $180 from $190 at Wells FargoRepligen price target lowered to $180 from $190 at Wells Fargo
UBS Analyst forecast on RGEN
Dan Leonard
UBS
UBS
$200→$195
Buy
65.56%
Upside
Reiterated
02/25/26
Repligen price target lowered to $195 from $200 at UBSRepligen price target lowered to $195 from $200 at UBS
KeyBanc Analyst forecast on RGEN
Paul Knight
KeyBanc
KeyBanc
$220
Buy
86.79%
Upside
Reiterated
02/25/26
KeyBanc Remains a Buy on Repligen (RGEN)
Evercore ISI Analyst forecast on RGEN
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$180→$170
Buy
44.34%
Upside
Reiterated
02/25/26
Repligen price target lowered to $170 from $180 at Evercore ISIRepligen price target lowered to $170 from $180 at Evercore ISI
Stifel Nicolaus Analyst forecast on RGEN
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$207
Buy
75.75%
Upside
Reiterated
02/25/26
Stifel Nicolaus Sticks to Its Buy Rating for Repligen (RGEN)
Canaccord Genuity Analyst forecast on RGEN
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$165
Hold
40.09%
Upside
Reiterated
02/25/26
Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
J.P. Morgan Analyst forecast on RGEN
Casey Woodring
J.P. Morgan
J.P. Morgan
$190→$180
Buy
52.83%
Upside
Reiterated
02/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (NASDAQ: AMRN), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)
Barclays Analyst forecast on RGEN
Luke Sergott
Barclays
Barclays
$200→$175
Buy
48.58%
Upside
Reiterated
02/25/26
Barclays Keeps Their Buy Rating on Repligen (RGEN)
Guggenheim Analyst forecast on RGEN
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
02/24/26
Repligen (RGEN) Gets a Hold from Guggenheim
TD Cowen Analyst forecast on RGEN
Brendan Smith
TD Cowen
TD Cowen
$200
Buy
69.81%
Upside
Reiterated
02/24/26
Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating
William Blair Analyst forecast on RGEN
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
02/24/26
Analysts' Top Healthcare Picks: Harmony Biosciences Holdings (HRMY), Repligen (RGEN)
Benchmark Co. Analyst forecast on RGEN
Robert Wasserman
Benchmark Co.
Benchmark Co.
―
Hold
―
Reiterated
10/29/25
Benchmark Co. Remains a Hold on Repligen (RGEN)
Leerink Partners Analyst forecast on RGEN
Puneet Souda
Leerink Partners
Leerink Partners
$200
Buy
69.81%
Upside
Reiterated
09/11/25
Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Insulet (PODD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum Analyst forecast on RGEN
Matt Hewitt
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
03/24/26
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Amylyx Pharmaceuticals Inc (AMLX)
H.C. Wainwright Analyst forecast on RGEN
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$208
Buy
76.60%
Upside
Reiterated
03/23/26
Repligen: Strong Execution, Innovation, and Cross‑Selling Momentum Support Sustained Growth and Reaffirmed Buy Rating
Wells Fargo Analyst forecast on RGEN
Brandon Couillard
Wells Fargo
Wells Fargo
$190→$180
Buy
52.83%
Upside
Reiterated
02/25/26
Repligen price target lowered to $180 from $190 at Wells FargoRepligen price target lowered to $180 from $190 at Wells Fargo
UBS Analyst forecast on RGEN
Dan Leonard
UBS
UBS
$200→$195
Buy
65.56%
Upside
Reiterated
02/25/26
Repligen price target lowered to $195 from $200 at UBSRepligen price target lowered to $195 from $200 at UBS
KeyBanc Analyst forecast on RGEN
Paul Knight
KeyBanc
KeyBanc
$220
Buy
86.79%
Upside
Reiterated
02/25/26
KeyBanc Remains a Buy on Repligen (RGEN)
Evercore ISI Analyst forecast on RGEN
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$180→$170
Buy
44.34%
Upside
Reiterated
02/25/26
Repligen price target lowered to $170 from $180 at Evercore ISIRepligen price target lowered to $170 from $180 at Evercore ISI
Stifel Nicolaus Analyst forecast on RGEN
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$207
Buy
75.75%
Upside
Reiterated
02/25/26
Stifel Nicolaus Sticks to Its Buy Rating for Repligen (RGEN)
Canaccord Genuity Analyst forecast on RGEN
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$165
Hold
40.09%
Upside
Reiterated
02/25/26
Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
J.P. Morgan Analyst forecast on RGEN
Casey Woodring
J.P. Morgan
J.P. Morgan
$190→$180
Buy
52.83%
Upside
Reiterated
02/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (NASDAQ: AMRN), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)
Barclays Analyst forecast on RGEN
Luke Sergott
Barclays
Barclays
$200→$175
Buy
48.58%
Upside
Reiterated
02/25/26
Barclays Keeps Their Buy Rating on Repligen (RGEN)
Guggenheim Analyst forecast on RGEN
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
02/24/26
Repligen (RGEN) Gets a Hold from Guggenheim
TD Cowen Analyst forecast on RGEN
Brendan Smith
TD Cowen
TD Cowen
$200
Buy
69.81%
Upside
Reiterated
02/24/26
Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating
William Blair Analyst forecast on RGEN
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
02/24/26
Analysts' Top Healthcare Picks: Harmony Biosciences Holdings (HRMY), Repligen (RGEN)
Benchmark Co. Analyst forecast on RGEN
Robert Wasserman
Benchmark Co.
Benchmark Co.
―
Hold
―
Reiterated
10/29/25
Benchmark Co. Remains a Hold on Repligen (RGEN)
Leerink Partners Analyst forecast on RGEN
Puneet Souda
Leerink Partners
Leerink Partners
$200
Buy
69.81%
Upside
Reiterated
09/11/25
Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Insulet (PODD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

3 Months
xxx
Success Rate
6/11 ratings generated profit
55%
Average Return
+3.47%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +3.47% per trade.
1 Year
Daniel AriasStifel Nicolaus
Success Rate
11/26 ratings generated profit
42%
Average Return
+12.59%
Copying Daniel Arias's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of +12.59% per trade.
2 Years
xxx
Success Rate
4/11 ratings generated profit
36%
Average Return
+3.88%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of +3.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGEN Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
2
3
3
Buy
17
10
17
14
10
Hold
4
0
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
10
21
19
15
In the current month, RGEN has received 13 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RGEN average Analyst price target in the past 3 months is 190.00.
Each month's total comprises the sum of three months' worth of ratings.

RGEN Financial Forecast

RGEN Earnings Forecast

Next quarter’s earnings estimate for RGEN is $0.39 with a range of $0.37 to $0.41. The previous quarter’s EPS was $0.49. RGEN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.
Next quarter’s earnings estimate for RGEN is $0.39 with a range of $0.37 to $0.41. The previous quarter’s EPS was $0.49. RGEN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.

RGEN Sales Forecast

Next quarter’s sales forecast for RGEN is $192.06M with a range of $187.80M to $196.53M. The previous quarter’s sales results were $197.91M. RGEN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.
Next quarter’s sales forecast for RGEN is $192.06M with a range of $187.80M to $196.53M. The previous quarter’s sales results were $197.91M. RGEN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.

RGEN Stock Forecast FAQ

What is RGEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Repligen Corp’s 12-month average price target is 190.00.
    What is RGEN’s upside potential, based on the analysts’ average price target?
    Repligen Corp has 61.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RGEN a Buy, Sell or Hold?
          Repligen Corp has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Repligen Corp’s price target?
            The average price target for Repligen Corp is 190.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $220.00 ,the lowest forecast is $165.00. The average price target represents 61.32% Increase from the current price of $117.78.
              What do analysts say about Repligen Corp?
              Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of RGEN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.